Development and optimization of a tamsulosin nanostructured lipid carrier loaded with saw palmetto oil and pumpkin seed oil for treatment of benign prostatic hyperplasia

References

• Alhakamy NA, Fahmy UA, Ahmed OAA. (2019). Attenuation of benign prostatic hyperplasia by optimized tadalafil loaded pumpkin seed oil-based self nanoemulsion: in vitro and in vivo evaluation. Pharmaceutics 11:1–13.
   Web of Science ®Google Scholar
• Aljaeid BM, Hosny KM. (2016). Miconazole-loaded solid lipid nanoparticles: formulation and evaluation of a novel formula with high bioavailability and antifungal activity. Int J Nanomedicine 11:441–7.
   PubMed Web of Science ®Google Scholar
• Almehmady AM, Elsisi AM. (2020). Development, optimization, and evaluation of tamsulosin nanotransfersomes to enhance its permeation and bioavailability. J Drug Deliv Sci Technol [Internet] 57:101667.
   Web of Science ®Google Scholar
• Almousallam M, Moia C, Zhu H. (2015). Development of nanostructured lipid carrier for dacarbazine delivery. Int Nano Lett 5:241–8.
   Web of Science ®Google Scholar
• Assaf SM, Sallam ASA, Ghanem AM. (2019). Design and evaluation of transdermal delivery system containing tamsulosin hydrochloride. J Drug Deliv Sci Technol [Internet] 51:524–34.
   Web of Science ®Google Scholar
• Baek J-S, Pham CV, Myung C-S, et al. (2015). Tadalafil-loaded nanostructured lipid carriers using permeation enhancers. Int J Pharm 495:701–9.
   PubMed Web of Science ®Google Scholar
• Braeckman J. (1994). The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res 55:776–85.
   Web of Science ®Google Scholar
• Chapple CR, Chartier-Kastler E. (2006). Pharmacokinetic profile of tamsulosin OCAS. BJU Int 98:9–12.
   Web of Science ®Google Scholar
• Costa CP, Moreira JN, Sousa Lobo JM, et al. (2021). Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies. Acta Pharm Sin B 11:925–40.
   PubMed Web of Science ®Google Scholar
• Danaei M, Dehghankhold M, Ataei S, et al. (2018). Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 10:1–17.
   Web of Science ®Google Scholar
• Giulianelli R, Pecoraro S, Sepe G, et al. (2012). Multicentre study on the efficacy and tolerability of an extract of Serenoa repens in patients with chronic benign prostate conditions associated with inflammation. Arch Ital di Urol Androl organo Uff [di] Soc Ital di Ecogr Urol e Nefrol. 84:94–8.
   PubMedGoogle Scholar
• Governa P, Giachetti D, Biagi M, et al. (2016). Hypothesis on Serenoa repens (Bartram) small extract inhibition of prostatic 5α-reductase through an in silico approach on 5β-reductase X-ray structure. PeerJ 4:e2698.
   PubMed Web of Science ®Google Scholar
• Hong H, Kim C-S, Maeng S. (2009). Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia. Nutr Res Pract 3:323–7.
   PubMed Web of Science ®Google Scholar
• Hosny KM, Bahmdan RH, Alhakamy NA, et al. (2020). Physically optimized nano-lipid carriers augment raloxifene and vitamin D oral bioavailability in healthy humans for management of osteoporosis. J Pharm Sci 109:2145–55.
   PubMed Web of Science ®Google Scholar
• Hosny KM, Sindi AM, Alkhalidi HM, et al. (2021). Development of omega-3 loxoprofen-loaded nanoemulsion to limit the side effect associated with NSAIDs in treatment of tooth pain. Drug Deliv 28:741–51.
   PubMed Web of Science ®Google Scholar
• Imran M, Iqubal MK, Imtiyaz K, et al. (2020). Topical nanostructured lipid carrier gel of quercetin and resveratrol: formulation, optimization, in vitro and ex vivo study for the treatment of skin cancer. Int J Pharm 587:119705.
   PubMed Web of Science ®Google Scholar
• Iqubal A, Syed MA, Najmi AK, et al. (2020). Nano-engineered nerolidol loaded lipid carrier delivery system attenuates cyclophosphamide neurotoxicity – probable role of NLRP3 inflammasome and caspase-1. Exp Neurol 334:113464.
   PubMed Web of Science ®Google Scholar
• Iqubal MK, Iqubal A, Imtiyaz K, et al. (2021). Combinatorial lipid-nanosystem for dermal delivery of 5-fluorouracil and resveratrol against skin cancer: delineation of improved dermatokinetics and epidermal drug deposition enhancement analysis. Eur J Pharm Biopharm 163:223–39.
   PubMed Web of Science ®Google Scholar
• Jangdey MS, Gupta A, Saraf S, et al. (2017). Development and optimization of apigenin-loaded transfersomal system for skin cancer delivery: in vitro evaluation. Artif Cells Nanomed Biotechnol 45:1452–62.
   PubMed Web of Science ®Google Scholar
• Khater U, Ramasamy R, Shah HN. (2020). Tamsulosin-induced priapism: report of two cases and review of literature. J Endourol Case Rep 6:174–6.
   PubMedGoogle Scholar
• Kumari R, Dash PP, Lal VK, et al. (2010). RP-HPLC method for the estimation of tamsulosin hydrochloride in tablet dosage form. Indian J Pharm Sci 72:785–7.
   PubMed Web of Science ®Google Scholar
• Leibbrand M, Siefer S, Schön C, et al. (2019). Effects of an oil-free hydroethanolic pumpkin seed extract on symptom frequency and severity in men with benign prostatic hyperplasia: a pilot study in humans. J Med Food 22:551–9.
   PubMed Web of Science ®Google Scholar
• Lepor H. (1998). Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 51:892–900.
   PubMed Web of Science ®Google Scholar
• Lim KB. (2017). Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 4:148–51.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. (2002). Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 62:135–67.
   PubMed Web of Science ®Google Scholar
• Martinelli C, Battaglini M, Battaglini M, et al. (2020). Development of nanostructured lipid carriers for the delivery of idebenone in autosomal recessive spastic ataxia of Charlevoix-Saguenay. ACS Omega 5:12451–66.
   PubMed Web of Science ®Google Scholar
• Mendes AI, Silva AC, Catita JAM, et al. (2013). Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: improving antifungal activity. Colloids Surfaces B Biointerfaces 111:755–63.
   PubMed Web of Science ®Google Scholar
• Michel MC, Korstanje C, Krauwinkel W. (2005). Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects. Eur Urol 4:9–14.
   Web of Science ®Google Scholar
• Morsi NM, Aboelwafa AA, Dawoud MHS. (2016). Improved bioavailability of timolol maleate via transdermal transfersomal gel: statistical optimization, characterization, and pharmacokinetic assessment. J Adv Res 7:691–701.
   PubMed Web of Science ®Google Scholar
• Motawea A, Borg T, Abd El-Gawad AEGH. (2018). Topical phenytoin nanostructured lipid carriers: design and development. Drug Dev. Ind. Pharm 44:144–157
   PubMed Web of Science ®Google Scholar
• Mura P, Maestrelli F, D’Ambrosio M, et al. (2021). Evaluation and comparison of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as vectors to develop hydrochlorothiazide effective and safe pediatric oral liquid formulations. Pharmaceutics 13:1–18.
   Web of Science ®Google Scholar
• Narayan P, Tewari A. (1998). A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 160:1701–6.
   PubMed Web of Science ®Google Scholar
• Narayan P, Tunuguntla HSGR. (2005). Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia. Rev Urol 7:S42–S8.
   PubMedGoogle Scholar
• Nawirska-Olszańska A, Kita A, Biesiada A, et al. (2013). Characteristics of antioxidant activity and composition of pumpkin seed oils in 12 cultivars. Food Chem 139:155–61.
   PubMed Web of Science ®Google Scholar
• Pangeni R, Choi SW, Jeon OC, et al. (2016). Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: Preparation and in vivo evaluation. Int J Nanomedicine 11:6379–99.
   PubMed Web of Science ®Google Scholar
• Qumber M, Alruwaili NK, Bukhari SNA, et al. (2021). BBD-based development of itraconazole loaded nanostructured lipid carrier for topical delivery: in vitro evaluation and antimicrobial assessment. J Pharm Innov 16:85–14.
   Web of Science ®Google Scholar
• Rahman HS, Rasedee A, How CW, et al. (2013). Zerumbone-loaded nanostructured lipid carriers: Preparation, characterization, and antileukemic effect. Int J Nanomedicine 8:2769–81.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. (2005). Benign prostatic hyperplasia: an overview. Rev Urol 7:S3–S14.
   PubMedGoogle Scholar
• Roehrborn CG, Casabé A, Glina S, et al. (2015). Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: secondary results from a 6-month, randomized, double-blind study comparing f. Int J Urol 22:582–7.
   PubMed Web of Science ®Google Scholar
• Shah RM, Eldridge DS, Palombo EA, et al. (2022). Stability mechanisms for microwave-produced solid lipid nanoparticles. Colloids Surfaces A Physicochem Eng Asp 643:128774.
   Web of Science ®Google Scholar
• Sinescu I, Geavlete P, Multescu R, et al. (2011). Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urol Int 86:284–9
   PubMed Web of Science ®Google Scholar
• Skinder D, Zacharia I, Studin J, et al. (2016). Benign prostatic hyperplasia: A clinical review. JAAPA 29:19–23.
   PubMedGoogle Scholar
• Tan F, Xu L, Liu Y, et al. (2022). Design of hydroxy-α-sanshool loaded nanostructured lipid carriers as a potential local anesthetic. Drug Deliv 29:743–53.
   PubMed Web of Science ®Google Scholar
• Teeranachaideekul V, Morakul B, Boonme P, et al. (2020). Effect of lipid and oil compositions on physicochemical properties and photoprotection of octyl methoxycinnamate-loaded nanostructured lipid carriers (NLC). J Oleo Sci 69:1627–39.
   PubMed Web of Science ®Google Scholar
• Vahlensieck W, Theurer C, Pfitzer E, et al. (2015). Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int 94:286–95.
   PubMed Web of Science ®Google Scholar
• Ye Z, Huang J, Zhou L, et al. (2019). Efficacy and safety of Serenoa repens extract among patients with benign prostatic hyperplasia in China: a multicenter, randomized, double-blind, placebo-controlled trial. Urology 129:172–9.
   PubMed Web of Science ®Google Scholar
• Yukuyama MN, Ghisleni DDM, Pinto TJA, et al. (2016). Nanoemulsion: process selection and application in cosmetics – a review. Int J Cosmet Sci 38:13–24.
   PubMed Web of Science ®Google Scholar